Future of Immunotherapy in Melanoma to Focus on Overcoming Resistance, Personalizing Regimens
With an estimated 5-year survival rate of 50% and an ongoing issue of resistance, next steps with immunotherapy in melanoma will focus on stratifying patients, personalizing therapy, and refining localized regimens.
Novel Triplets May Overcome Resistance to Targeted Therapy in BRAF+ Melanoma
The addition of anti–PD-1/PD-L1 to combination BRAF and MEK inhibition has been shown to improve progression-free survival and duration of response in patients with BRAF-mutated melanoma, suggesting potential to overcome resistance to targeted approaches.
Spartalizumab Plus Dabrafenib/Trametinib Impresses in BRAF+ Melanoma With Poor PrognosisNovember 27th 2019
A triplet combining the PD-1 inhibitor spartalizumab with dabrafenib and trametinib led to a 12-month overall survival rate of 86.1% for patients with previously untreated advanced BRAF V600–mutant melanoma.
Cobimetinib/Vemurafenib OS Benefit Sustained at 5 Years in BRAF+ MelanomaNovember 25th 2019
The combination of cobimetinib (Cotellic) and vemurafenib (Zelboraf) maintained an advantage for overall survival and objective response rate in patients with BRAF-positive melanoma versus vemurafenib alone.
CR With Dabrafenib/Trametinib Linked to Long-Term Survival in BRAF+ MelanomaNovember 24th 2019
Patients with unresectable or metastatic BRAF V600-mutant melanoma who achieve a complete response to dabrafenib (Tafinlar) plus trametinib (Mekinist) are more likely to have improved survival outcomes at 5 years.
Dr. McArthur Discusses Subpopulation Data from coBRIM Trial in Advanced MelanomaNovember 23rd 2019
Grant McArthur, PhD, discusses significant results from the final analysis of the coBRIM trial, which evaluated the 5-year survival data of cobimetinib plus vemurafenib in patients with BRAF V600-mutated advanced melanoma.
Neoadjuvant T-VEC May Improve Survival in Advanced MelanomaNovember 23rd 2019
Talimogene laherparepvec (T-VEC; Imlygic) prior to surgery was associated with improved recurrence-free survival and overall survival compared with surgery alone in patients with resectable advanced melanoma.
Dr. Sullivan Discusses Role of Dabrafenib Plus Trametinib in MelanomaNovember 23rd 2019
Ryan J. Sullivan, MD, discusses the significance of the BRAF/MEK combination dabrafenib and trametinib, which was the first BRAF/MEK inhibitor regimen to be approved by the FDA for the treatment of patients with BRAF V600E–positive stage III melanoma following complete resection.
Dr. Danuser Discusses Impact of RacP29S Mutation in MelanomaNovember 22nd 2019
Gaudenz Danuser, PhD, discusses how the activation of RacP29S impacts the treatment of patients with melanoma. His lab has been studying the Rac molecule for around 20 years. The RacP29S mutation most commonly appears in melanoma, but it has since been discovered in a few other cancer types as well.
Dr. Warner Discusses Findings from COMBI-i Trial in MelanomaNovember 22nd 2019
Allison Betof Warner, MD, PhD, discusses the excitement surrounding the findings from the COMBI-i trial that was presented at the 2019 ASCO Annual Meeting. This trial investigated the combination of PD-1 inhibitor spartalizumab with dabrafenib plus trametinib in patients with advanced BRAF V6000mutant melanoma.
Dr. Shoushtari on the Data from the First-in-Human Trial for Tebentafusp in Advanced MelanomaNovember 22nd 2019
Alexander N. Shoushtari, MD, discusses the significance of the findings from the first-in-human trial evaluating tebentafusp, a TCR–CD3 bispecific, in patients with advanced melanoma.
Adjuvant Dabrafenib/Trametinib RFS Benefit Persists Across Melanoma Subgroups
A doubling in 3-year relapse-free survival rates remained consistent across patient subgroups treated with dabrafenib and trametinib, when compared with placebo, for patients with BRAF-mutant stage III melanoma.
Dr. Amaria on Genetically Modified TILs in MelanomaOctober 21st 2017
Rodabe N. Amaria, MD, department of Melanoma Oncology, division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses using genetically modified tumor infiltrating lymphocytes (TILs) in patients with advanced melanoma.
Dr. Schadendorf on the Efficacy of Targeted Therapy Plus Checkpoint InhibitorsOctober 21st 2017
Dirk Schadendorf, MD, head of department for Dermatology, Venerology and Allergology, University Hospital Essen, Germany, discusses the efficacy of combining targeted therapy with checkpoint inhibitors for patients with melanoma.
Novel Combinations Mark Next Step for MelanomaOctober 20th 2017
Immunotherapy has led a transformation for melanoma care but combinations of anti–PD-1 and CTLA-4 agents are toxic and biomarkers are not available to help personalized treatment, calling for further research into less toxic and more effective options.